Head and neck cancer is a group of heterogeneous cancers that begin in the regions around the head & neck.

Common tumor sites include oral cavity, lip, pharynx (oropharynx and hypopharynx) and larynx. Approximately 90% of head and neck cancers are squamous cell carcinomas.

Oncology guidelines recommend involvement of a multidisciplinary team in the care of head and neck cancer patients given the complexities of the disease, need for multimodal treatment approaches, and critical physiologic functions affected by treatment decisions.

The unique challenges faced by head and neck cancer patients give rise to important considerations that can drive treatment decisions. A clear understanding of patient preferences, stakeholder influences and key unmet needs are essential in developing a winning strategy for new treatment approaches in this space. Cerner Enviza’s custom consultative research can help bring remarkable clarity to your questions in head and neck cancer.